Alzheimer's disease multi indicator joint testing reagent
Clinical significance
1) Early screening and diagnosis of Alzheimer's disease (AD): Detecting peripheral blood biomarkers can identify corresponding pathological changes before clinical symptoms manifest, thereby aiding in the early screening of AD and providing an opportunity for timely intervention; 2) Assessment related to AD treatment: Following targeted drug therapy or other related treatments, the combined detection of peripheral blood biomarkers allows for dynamic monitoring of the treatment's effectiveness and prognosis in AD patients; 3) Primary healthcare: Combined with health checkups, elderly individuals can undergo regular annual screening and receive early intervention.
Applicable population
Patients in neurology/neuroscience, geriatrics, rehabilitation, physical examination departments, etc.
Multi indicator joint detection
Requires only 25 μL of sample, simultaneously detects multiple Alzheimer's disease (AD) biomarkers, including Aβ1-42, Aβ1-40, p-Tau-181, and α-synuclein.
技术方法成熟
适用范围广
Based on flow cytometry technology, it offers superior performance, accurate results, high sensitivity, and easy operation.
